Age group, n (%) |
Age group, n (%) |
Age group, n (%) |
Age group, n
(%) |
65–74 |
87 (60.8) |
52 (58.4) |
0.82 |
≥ 75 |
56 (39.2) |
37 (41.6) |
|
Sex, n (%) |
Sex, n (%) |
Sex,
n (%) |
Sex, n (%) |
Female |
104 (72.7) |
68 (76.4) |
0.64 |
Male |
39 (27.3) |
21 (23.6) |
|
Smoking status, n (%) |
Smoking status,
n (%) |
Smoking status, n (%) |
Smoking status, n (%) |
Brinkman index <400 |
108 (75.5) |
60 (67.4) |
0.23 |
Brinkman index ≥400 |
35 (24.5) |
29 (32.6) |
|
ECOG-PS, n (%) |
ECOG-PS, n (%) |
ECOG-PS, n (%) |
ECOG-PS, n
(%) |
0/1 |
116 (81.1) |
63 (70.8) |
0.097 |
≥ 2 |
27 (18.9) |
26 (29.2) |
|
BMI, n (%) |
BMI, n (%) |
BMI,
n (%) |
BMI, n (%) |
< 18.5 |
36 (25.2) |
18 (20.2) |
0.13 |
≥ 18.5 |
94 (65.7) |
68 (76.4) |
|
Histological subtypes, n (%) |
Histological
subtypes, n (%) |
Histological subtypes, n (%) |
Histological subtypes, n (%) |
Adenocarcinoma |
133 (93.0) |
83 (93.3) |
1.00 |
Other |
10 (7.0) a
|
6 (6.7) b
|
|
Staging, n (%) |
Staging, n (%) |
Staging, n (%) |
Staging, n
(%) |
III |
7 (4.9) |
1 (1.1) |
0.33 |
IVA |
31 (21.7) |
15 (16.9) |
|
IVB |
71 (49.7) |
50 (26.2) |
|
Recurrence |
34 (23.8) |
23 (25.8) |
|
Number of organs involved in metastasis, n (%) |
Number of organs involved in metastasis, n (%) |
Number of organs involved in metastasis, n (%) |
Number of organs involved in metastasis, n
(%) |
0/1 |
79 (55.2) |
40 (44.9) |
0.16 |
≥ 2 |
64 (44.8) |
49 (55.1) |
|
Presence of brain metastasis, n (%) |
Presence
of brain metastasis, n (%) |
Presence of brain
metastasis, n (%) |
Presence of brain metastasis,
n (%) |
Yes |
40 (28.0) |
25 (28.1) |
1.00 |
Presence of bone metastasis, n (%) |
Presence
of bone metastasis, n (%) |
Presence of bone
metastasis, n (%) |
Presence of bone metastasis,
n (%) |
Yes |
47 (32.9) |
38 (42.7) |
0.17 |
Presence of liver metastasis, n (%) |
Presence
of liver metastasis, n (%) |
Presence of liver
metastasis, n (%) |
Presence of liver metastasis,
n (%) |
Yes |
24 (16.8) |
17 (19.1) |
0.79 |
EGFR mutation status, n (%)
|
EGFR mutation status, n (%)
|
EGFR mutation status, n (%)
|
EGFR mutation status, n (%)
|
Exon 19 del |
56 (39.2) |
36 (40.4) |
0.88 |
Exon 21 L858R |
74 (51.7) |
46 (51.7) |
|
Other |
11 (8.4) c
|
7 (7.9) d
|
|
Initially chosen EGFR-TKIs, n (%) |
Initially
chosen EGFR-TKIs, n (%) |
Initially chosen EGFR-TKIs,
n (%) |
Initially chosen EGFR-TKIs, n
(%) |
Gefitinib |
92 (64.3) |
64 (71.9) |
0.16 |
Erlotinib |
22 (15.4) |
16 (18.0) |
|
Afatinib |
9 (6.3) |
1 (1.1) |
|
Osimertinib |
20 (14.0) |
8 (9.0) |
|
Combination with other
antitumor agents, n (%) |
Combination with other
antitumor agents, n (%) |
Combination with other
antitumor agents, n (%) |
Combination with other
antitumor agents, n (%) |
Yes |
24 (16.8) |
7 (78.7) |
0.081 |
Lines of EGFR-TKIs use |
Lines of EGFR-TKIs use |
Lines of EGFR-TKIs use |
Lines of EGFR-TKIs
use |
First |
117 (81.8) |
71 (79.8) |
0.83 |
Second or later |
26 (18.2) |
18 (20.2) |
|
Osimertinib use in clinical course, i (%) |
Osimertinib use in clinical course, i (%) |
Osimertinib use in clinical course, i (%) |
Osimertinib use in clinical course, i (%) |
Yes |
48 (33.6) |
18 (20.2) |
0.041 |
CCI, n (%) |
CCI, n (%) |
CCI,
n (%) |
CCI, n (%) |
≤ 6 |
99 (69.2) |
44 (49.4) |
0.004 |
≥ 7 |
54 (37.8) |
45 (50.6) |
|
GRIm-Score, n (%) |
GRIm-Score, n (%) |
GRIm-Score, n (%) |
GRIm-Score, n
(%) |
0/1 |
121 (84.6) |
68 (76.4) |
0.25 |
2/3 |
20 (14.0) |
20 (22.5) |
|